PURPOSE: The purpose of the study was to evaluate the ability of baseline perfusion defect score (DS) on SPECT to predict the development of severe symptomatic radiation pneumonitis (RP) and to evaluate changes in perfusion on SPECT as a method of lung perfusion function assessment after curative radiotherapy (RT) for non-small-cell lung cancer (NSCLC). METHODS: Patients with NSCLC undergoing curative RT were included prospectively. Perfusion SPECT/CT and global pulmonary function tests (PFT) were performed before RT and four times during follow-up. Functional activity on SPECT was measured using a semiquantitative perfusion DS. Pulmonary morbidity was graded by the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4 for pneumonitis. Patients were divided into two groups according to the severity of RP. RESULTS: A total of 71 consecutive patients were included in the study. Baseline DS was associated with chronic obstructive pulmonary disease. A significant inverse correlation was found between baseline DS and forced expiratory volume in 1 s and diffusing capacity of the lung for carbon monoxide. Patients with severe RP had significantly higher baseline total lung DS (mean 5.43) than those with no or mild symptoms (mean DS 3.96, p < 0.01). PFT results were not different between these two groups. The odds ratio for total lung DS was 7.8 (95% CI 1.9 - 31) demonstrating the ability of this parameter to predict severe RP. Adjustment for other potential confounders known to be associated with increased risk of RP was performed and did not change the odds ratio. The median follow-up time after RT was 8.4 months. The largest DS increase of 13.3% was associated with severe RP at 3 months of follow-up (p < 0.01). The development of severe RP during follow-up was not associated with changes in PFT results. CONCLUSION: Perfusion SPECT is a valuable method for predicting severe RP and for assessing changes in regional functional perfusion after curative RT comparable with global PFT.
PURPOSE: The purpose of the study was to evaluate the ability of baseline perfusion defect score (DS) on SPECT to predict the development of severe symptomatic radiation pneumonitis (RP) and to evaluate changes in perfusion on SPECT as a method of lung perfusion function assessment after curative radiotherapy (RT) for non-small-cell lung cancer (NSCLC). METHODS:Patients with NSCLC undergoing curative RT were included prospectively. Perfusion SPECT/CT and global pulmonary function tests (PFT) were performed before RT and four times during follow-up. Functional activity on SPECT was measured using a semiquantitative perfusion DS. Pulmonary morbidity was graded by the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4 for pneumonitis. Patients were divided into two groups according to the severity of RP. RESULTS: A total of 71 consecutive patients were included in the study. Baseline DS was associated with chronic obstructive pulmonary disease. A significant inverse correlation was found between baseline DS and forced expiratory volume in 1 s and diffusing capacity of the lung for carbon monoxide. Patients with severe RP had significantly higher baseline total lung DS (mean 5.43) than those with no or mild symptoms (mean DS 3.96, p < 0.01). PFT results were not different between these two groups. The odds ratio for total lung DS was 7.8 (95% CI 1.9 - 31) demonstrating the ability of this parameter to predict severe RP. Adjustment for other potential confounders known to be associated with increased risk of RP was performed and did not change the odds ratio. The median follow-up time after RT was 8.4 months. The largest DS increase of 13.3% was associated with severe RP at 3 months of follow-up (p < 0.01). The development of severe RP during follow-up was not associated with changes in PFT results. CONCLUSION: Perfusion SPECT is a valuable method for predicting severe RP and for assessing changes in regional functional perfusion after curative RT comparable with global PFT.
Authors: L B Marks; M Fan; R Clough; M Munley; G Bentel; R E Coleman; R Jaszczak; D Hollis; M Anscher Journal: Int J Radiat Biol Date: 2000-04 Impact factor: 2.694
Authors: Katrien De Jaeger; Yvette Seppenwoolde; Liesbeth J Boersma; Sara H Muller; Paul Baas; José S A Belderbos; Joos V Lebesque Journal: Int J Radiat Oncol Biol Phys Date: 2003-04-01 Impact factor: 7.038
Authors: Ellen D Yorke; Andrew Jackson; Kenneth E Rosenzweig; Louise Braban; Steven A Leibel; C Clifton Ling Journal: Int J Radiat Oncol Biol Phys Date: 2005-06-04 Impact factor: 7.038
Authors: Mike E Robbins; Judy K Brunso-Bechtold; Ann M Peiffer; Christina I Tsien; Janet E Bailey; Lawrence B Marks Journal: Radiat Res Date: 2012-02-21 Impact factor: 2.841
Authors: L B Marks; D P Spencer; G W Sherouse; G Bentel; R Clough; K Vann; R Jaszczak; R E Coleman; L R Prosnitz Journal: Int J Radiat Oncol Biol Phys Date: 1995-08-30 Impact factor: 7.038
Authors: Gurleen Dhami; Jing Zeng; Hubert J Vesselle; Paul E Kinahan; Robert S Miyaoka; Shilpen A Patel; Ramesh Rengan; Stephen R Bowen Journal: Strahlenther Onkol Date: 2017-03-02 Impact factor: 3.621
Authors: Daniel Rocky Owen; Phillip S Boonstra; Benjamin L Viglianti; James M Balter; Matthew J Schipper; William C Jackson; Issam El Naqa; Shruti Jolly; Randall K Ten Haken; Feng-Ming Spring Kong; Martha M Matuszak Journal: Int J Radiat Oncol Biol Phys Date: 2018-06-01 Impact factor: 7.038
Authors: Katherina P Farr; Katrina West; Roland Yeghiaian-Alvandi; David Farlow; Rachel Stensmyr; Andrew Chicco; Eric Hau Journal: Phys Imaging Radiat Oncol Date: 2019-09-20